This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A look at the ALS landscape with focus on AMX0035 (Relyvrio) in light of its recent FDA approval

Ticker(s): AMLX

Who's the expert?

Institution: University of California San Francisco

  • Assistant Program Director of the UCSF Neurology Residency.
  • Manages patients with disorders of the nerve, muscle, neuromuscular junction, and spine.
  • Cares for general Neurology patients at the Zuckerberg San Francisco General Hospital, and Neuromuscular and ALS patients in the Fresno region.
  • Treats 45-50 patients with ALS
  • Prescribed Evrysdi to 1 patient

Interview Goal
Discuss AMX0035 in the ALS landscape

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.